Twist Bioscience Corporation
NASDAQ:TWSTMedical - Diagnostics & Research
+$2.15 today
- Market cap
- $7.66B
- Beta
- 2.21
- P/E (TTM)
- -64.5
- EPS (TTM)
- -$1.32
Volume 2.23M
Average 1.53M
TWST Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Twist Bioscience CorporationNASDAQ: TWST
Cash & Equivalents · Q4 FY2026 · quarter ended Sep 2026
Cash & equivalents rises 191.7% from a year ago
Cash & equivalents stood at $533.99M at the end of Q4 FY2026, up 191.7% from a year earlier and up 354.7% from the prior quarter. Over 3 fiscal years it compounded at +23.1% a year.
Context
- Cash & equivalents amounted to 47.6% of total assets at the end of Q4 FY2026, up 19.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +191.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2026
- 533.99M USD
- Year-over-year change
- +191.7%
- 4-year CAGR
- +9.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 533.99M | +191.7% |
| FY2025 | 2025-09-30 | 183.05M | -19.1% |
| FY2024 | 2024-09-30 | 226.32M | -21.0% |
| FY2023 | 2023-09-30 | 286.47M | -24.4% |
| FY2022 | 2022-09-30 | 378.69M | — |
Cash & Equivalents vs competitors
How TWST compares with its peers on the latest reported figures
- TWST's Sep 2026 cash & equivalents of $533.99M is the lowest of the 2 companies compared; the peer median is $606.78M.
- Its year-over-year change of +191.7% is the highest of 2, against a peer median of -14.4%.
- Cash & equivalents amounts to 47.6% of total assets for TWST, versus a peer median of 20.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $606.78M | -14.4% | +2.6% | 20.6% | |
| Sep 2026 | $533.99M | +191.7% | +23.1% | 47.6% | |
| Peer median (excluding TWST) | $606.78M | -14.4% | +2.6% | 20.6% | |
Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 378.69M | 286.47M | 226.32M | 183.05M | 533.99M |
| Short-term Investments | 126.28M | 49.94M | 50.08M | 49.39M | 47.92M |
| Net Receivables | 40.29M | 44.06M | 34.9M | 57.32M | 70.19M |
| Inventory | 39.31M | 32.06M | 24.08M | 28.31M | 46.41M |
| Other Current Assets | 0 | 11.72M | 11.4M | 14.9M | 38.71M |
| Total Current Assets | 596.48M | 424.26M | 346.78M | 332.97M | 737.22M |
| Property, Plant & Equipment (Net) | 214.39M | 203.36M | 161.35M | 151.66M | 191.6M |
| Goodwill | 85.81M | 85.81M | 85.81M | 82.2M | 82.2M |
| Intangible Assets | 59.74M | 54.48M | 14.48M | 13.43M | 34.16M |
| Long-term Investments | 0 | 2.81M | 1.53M | 54.34M | 68.09M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.96M | 5.68M | 4.38M | 7.28M | 8.54M |
| Total Non-current Assets | 364.9M | 352.15M | 267.55M | 308.9M | 384.58M |
| Total Assets | 961.38M | 776.4M | 614.32M | 641.86M | 1.12B |
| Account Payables | 20.09M | 14.05M | 1.63M | 11.09M | 24.85M |
| Short-term Debt | 0 | 0 | 0 | 13.82M | 0 |
| Tax Payables | 3.66M | 4.37M | 2.73M | 0 | 0 |
| Deferred Revenue | 3.48M | 3M | 2.13M | 6.88M | 0 |
| Other Current Liabilities | 39.62M | 26.25M | 34.61M | 23.78M | 54.19M |
| Total Current Liabilities | 90.66M | 73.32M | 71.01M | 91.41M | 125.81M |
| Long-term Debt | 0 | 0 | 0 | 61.75M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 60K | 475K | 407K | (46M) | 21.45M |
| Total Non-current Liabilities | 81.33M | 79.65M | 70.63M | 77.5M | 107.98M |
| Total Liabilities | 171.99M | 152.97M | 141.63M | 168.9M | 233.79M |
| Common Stock | 0 | 0 | 0 | 0 | 1K |
| Retained Earnings | (828.42M) | (1.03B) | (1.24B) | (1.32B) | (1.45B) |
| Accumulated OCI | (1.84M) | (756K) | (522K) | (627K) | (680K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 2.34B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 789.39M | 623.43M | 472.69M | 472.96M | 888.02M |
| Total Debt | 94.91M | 94.07M | 85.03M | 137.32M | 94.99M |
| Net Debt | (283.78M) | (192.4M) | (141.29M) | (45.73M) | (439.01M) |
Twist Bioscience Corporation
NASDAQ:TWST
Intrinsic Alpha fair value
Locked
Current Price
$116.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.